Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Poultry Gut Health Integrity Solutions – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Poultry Gut Health Integrity Solutions market, including market size, share, demand, industry development status, and forecasts for the next few years.
Poultry producers and animal nutritionists face a persistent challenge: maintaining flock health and productivity while reducing or eliminating antibiotic growth promoters (AGPs) due to regulatory restrictions and consumer demand for antibiotic-free meat. Suboptimal gut health leads to poor feed efficiency, increased mortality, higher veterinary costs, and reduced weight gain—directly impacting farm profitability. Poultry Gut Health Integrity Solutions address this need through specialized feed additives, nutritional strategies, and management practices designed to maintain and enhance the structural and functional health of the digestive tract. These solutions optimize nutrient absorption, support a balanced gut microbiome, and strengthen the intestinal barrier, reducing the risk of digestive disorders and infections. This report analyzes market dynamics across solution types (probiotics, prebiotics, enzymes, organic acids, phytogenics), poultry categories (broilers, breeders and layers), and key drivers including AGP bans and rising protein demand.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5181150/poultry-gut-health-integrity-solutions
Market Sizing and Growth Trajectory (2024-2031)
The global market for Poultry Gut Health Integrity Solutions was estimated to be worth US$ 4,882 million in 2024 and is forecast to a readjusted size of US$ 8,881 million by 2031 with a CAGR of 8.9% during the forecast period 2025-2031. Poultry Gut Health Integrity Solutions are specialized feed additives, nutritional strategies, and management practices designed to maintain and enhance the structural and functional health of the digestive tract in poultry. These solutions aim to optimize nutrient absorption, support a balanced gut microbiome, and strengthen the intestinal barrier, thereby reducing the risk of digestive disorders and infections. By promoting gut integrity, they help improve feed efficiency, growth performance, and overall flock resilience, while minimizing the need for antibiotics or other therapeutic interventions. Such solutions often combine probiotics, prebiotics, enzymes, and natural bioactive compounds to create a holistic approach to digestive health, ensuring poultry maintain optimal physiological function and productivity throughout their growth cycle.
Industry Deep-Dive: Manufacturing Differentiation and Solution Mechanisms
A critical industry distinction emerges between process manufacturing (fermentation for probiotics, enzymes, and organic acids) and blending/pelletizing (finished feed additive production). Probiotic production exemplifies process manufacturing: bacterial strains (Lactobacillus, Bacillus, Bifidobacterium, Enterococcus) are fermented in bioreactors (5,000-50,000L capacity) under strict aseptic conditions (temperature 30-40°C, pH 4.5-7.0), then freeze-dried or spray-dried to achieve viable cell counts exceeding 10¹⁰ CFU/g. Enzyme production follows similar principles, with fungal or bacterial fermentation yielding proteases, phytases, xylanases, and glucanases. Organic acids (formic, propionic, butyric, citric) are synthesized via chemical or fermentation routes, requiring distillation and purification to food-grade standards (>99.5% purity).
In contrast, finished feed additive manufacturing follows discrete blending principles: precise weighing of active ingredients (probiotics, enzymes, organic acids, phytogenics) with carriers (calcium carbonate, wheat middlings, rice hulls), mixing in ribbon or paddle blenders to achieve coefficient of variation <5%, and packaging in moisture-barrier bags or bulk totes. This bifurcation creates distinct quality control parameters: probiotic manufacturers focus on viability (minimum 10⁹ CFU/g at manufacture, 10⁷ CFU/g at expiration) and strain purity; finished formulators focus on homogeneity, stability during feed pelleting (heat tolerance up to 80°C), and compatibility with other feed ingredients.
Recent Industry Data (Last 6 Months)
- May 2025: The European Commission finalized the revision of Regulation (EC) No 1831/2003 on feed additives, establishing new efficacy requirements for probiotic strains used in poultry gut health, including mandatory strain-level genomic characterization and field trial data (minimum 3 commercial farms, 5,000 birds per trial).
- March 2025: China’s Ministry of Agriculture and Rural Affairs (MARA) announced accelerated approval pathways for phytogenic feed additives (essential oils, plant extracts) with demonstrated gut health benefits, reducing registration time from 24 to 12 months for products with existing GRAS status in EU or US.
- February 2025: Evonik launched a new tributyrate-based gut health solution (butyric acid triglyceride) for broilers, demonstrating 6.2% improvement in feed conversion ratio (FCR) and 8.5% reduction in necrotic enteritis lesions in field trials across 12 commercial farms (n=480,000 birds).
- Market dynamic: Asia-Pacific dominated global poultry gut health solution demand in 2025 (42% market share), driven by China’s “shutdown of livestock antibiotics in feed” policy (effective July 2020, full compliance by 2025) and Southeast Asia’s expanding integrated poultry operations (CP Group, Japfa, Charoen Pokphand Foods).
Typical User Cases and Technical Challenges
- Case 1 (Broilers – AGP Replacement): A Brazilian integrated poultry producer (2.4 million broilers per cycle) replaced antibiotic growth promoters (virginiamycin) with a multi-species probiotic blend (Bacillus subtilis, B. licheniformis, Lactobacillus reuteri at 10⁸ CFU/kg feed) across 8 consecutive flocks. Results over 12 months: average daily gain (ADG) maintained at 58g/day (vs. 59g/day with AGP), FCR improved from 1.62 to 1.60, and mortality due to necrotic enteritis decreased 41% (from 2.7% to 1.6%). Economic analysis showed net benefit of $0.18 per bird—equivalent to $432,000 annually for the operation.
- Case 2 (Layers – Egg Production): A German layer operation (120,000 hens, conventional cages) incorporated a gut health solution combining organic acids (formic + propionic at 0.3% of feed) and a phytogenic blend (thyme, oregano, citrus essential oils). After 24 weeks: laying rate increased from 91% to 94.5%, feed intake per dozen eggs decreased from 1.52kg to 1.44kg, and dirty egg rate (fecal contamination) decreased 55%. The producer achieved “antibiotic-free” certification, enabling premium pricing (+€0.08 per egg) in German retail.
- Technical Hurdle: Heat stability during feed pelleting (typically 70-90°C, 30-90 seconds) remains a primary limitation for probiotic viability. Standard Bacillus strains survive pelleting reasonably well (60-80% recovery) due to endospore formation, but Lactobacillus and Bifidobacterium species (non-spore-forming) show survival rates below 10%. Post-pelleting liquid application (spray-on technology) addresses this but requires capital investment ($150,000-300,000 per feed mill). Evonik and DSM have developed coated probiotic formulations with lipid or polymer encapsulation, achieving >70% survival at 85°C for 60 seconds—though at 15-20% cost premium.
Policy and Regulatory Update (2024-2025)
- EU Farm to Fork Strategy (2025 implementation phase): Targets 50% reduction in EU sales of antimicrobials for farmed animals by 2030 (baseline 2018). Member states must report annual antibiotic use by livestock category, with financial penalties for exceeding national targets—directly accelerating adoption of gut health solutions.
- US FDA Guidance for Industry #263 (May 2025): Final guidance on labeling of “medically important” antimicrobials in animal feed, requiring veterinary feed directive (VFD) for any therapeutic use, while reaffirming that probiotics, prebiotics, enzymes, and phytogenics remain unregulated as feed additives (not requiring VFD).
- Brazil’s Normative Instruction No. 128 (January 2025): Prohibits the use of colistin and tylosin as growth promoters in poultry feed, expanding Brazil’s list of banned AGPs to 15 active ingredients. Brazil is the world’s largest chicken exporter (4.6 million tons in 2024), creating significant market pull for gut health alternatives.
独家观察 / Exclusive Insight: Industry Stratification by Solution Type, Poultry Category, and Geography
A clear market stratification is emerging across solution types, poultry categories, and geographic regions. Probiotics and prebiotics (approx. 38% of global revenue) dominate the broiler segment (70% of probiotic sales), valued for AGP replacement efficacy and microbiome modulation. Enzymes (approx. 25% of revenue) lead in phytase (improving phosphorus utilization) and xylanase (degrading non-starch polysaccharides), with near-universal adoption in commercial poultry feed (penetration >85% in EU, US, Brazil). Organic acids (approx. 18% of revenue) show strongest growth in water acidification applications for pathogen control (Salmonella, Campylobacter). Phytogenics (approx. 12% of revenue, fastest-growing at 11.5% CAGR) are gaining traction in premium “natural” and “clean-label” poultry products, particularly in EU markets.
Broiler segment (approx. 72% of global revenue) is characterized by: (1) high volume, low margin dynamics (average $0.15-0.35 per bird for gut health solutions), (2) focus on FCR improvement (each 0.01 FCR reduction equals $0.004-0.006 per bird profit), (3) channel preference for integrated producers and feed mills. Breeder and layer segment (approx. 22% of revenue) shows distinct dynamics: (1) higher value per bird (layer produces 300-350 eggs over lifetime), (2) emphasis on hen health and eggshell quality, (3) slower adoption of AGP alternatives due to longer production cycles (60-80 weeks vs. 35-42 days for broilers).
Geographically, Europe leads in adoption of antibiotic-free gut health solutions (38% market share), driven by EU AGP bans (2006 for growth promotion, 2022 for metaphylaxis). North America follows at 30% share, with accelerating transition as major retailers (Tyson, Perdue, Pilgrim’s) commit to “no antibiotics ever” (NAE) chicken. Asia-Pacific represents 25% share but is the fastest-growing region (+10.2% CAGR), led by China’s AGP phase-out and Southeast Asia’s rising poultry production (Vietnam +8%, Indonesia +6% annually).
By 2028, the phytogenics segment is projected to reach 18% market share, driven by consumer preference for “natural” production systems and regulatory tailwinds (EU approval of 20+ phytogenic feed additives under new EFSA guidelines). Notably, a distinct synbiotic sub-segment (probiotic + prebiotic combinations) is emerging—products specifically formulated to enhance probiotic colonization and persistence in the poultry gut. Companies including Novonesis (formerly Novozymes + Chr. Hansen), Lesaffre, and Lallemand have launched synbiotic products with clinical data showing 15-20% greater efficacy than probiotics alone, commanding price premiums of 25-40% over standard products. This segment, currently 5-7% of the probiotic market, is projected to reach 15% by 2030, as poultry nutritionists seek differentiated solutions in an increasingly crowded gut health marketplace.
The Poultry Gut Health Integrity Solutions market is segmented as below:
Evonik
Trouw Nutrition
DSM
Alltech
Novonesis
Bluestar Adisseo
Eastman
Cargill
Kemin Industries
Perstorp
Novus International
Orffa
Merck Animal Health
Danisco Animal Nutrition & Health (IFF)
Lallemand
EW Nutrition
Balchem
Impextraco
Alivira Animal Health
Biochem
Biorigin
Asahi Biocycle
Amlan International
AB Vista
Lesaffre
Segment by Type
Probiotics and Prebiotics
Enzymes
Organic Acids
Phytogenics
Others
Segment by Application
Broilers
Breeders and Layers
Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
